Edition:
United States

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

2.95USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.95
Open
$2.95
Day's High
$3.03
Day's Low
$2.95
Volume
9,072
Avg. Vol
22,091
52-wk High
$6.20
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Tracon Pharmaceuticals Inc ::Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget.Tracon Pharmaceuticals -‍in trial, 4 of 17 patients experienced partial response to treatment, eight additional patients (8/17, 47%) had stable disease​.Tracon Pharmaceuticals -‍in trial, combination of trc102,fludara produced evidence of tumor DNA damage that appeared to correlate with antitumor activity​.  Full Article

Tracon Pharma reports third quarter financial results
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals reports third quarter financial results and provides corporate update.Tracon Pharmaceuticals Inc-qtrly ‍shr $0.07​.  Full Article

683 Capital Management reports 5.4 pct passive stake in Tracon Pharmaceuticals
Thursday, 28 Sep 2017 05:10pm EDT 

Sept 28 (Reuters) - Tracon Pharmaceuticals Inc :683 Capital Management Llc reports 5.4% passive stake in Tracon Pharmaceuticals Inc as of Sept 18, 2017 - SEC filing‍​.  Full Article

Tracon Pharmaceuticals files for offering of up to $14.33 mln of co's common stock‍​
Tuesday, 5 Sep 2017 06:07am EDT 

Sept 5 (Reuters) - Tracon Pharmaceuticals Inc :Files for offering of up to $14.33 million of co's common stock‍​ - SEC filing.  Full Article

Tracon Pharmaceuticals announces positive results for phase 1/2 trial of TRC105 and Nexavar
Wednesday, 16 Aug 2017 08:00am EDT 

Aug 16 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals announces positive results from National Cancer Institute Phase 1/2 trial of TRC105 and Nexavar in Hepatocellular cancer published in Clinical Cancer Research.Tracon Pharmaceuticals Inc - ‍NCI study researchers concluded that combination of TRC105 and Nexavar was well-tolerated​.Tracon Pharmaceuticals Inc - ‍We expect to report data from Tracon-sponsored multicenter phase 1/2 HCC trial in early 2018​.  Full Article

Tracon Pharmaceuticals qtrly net loss per share $0.40
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals reports second quarter financial results and provides corporate update.Qtrly net loss per share $0.40.Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

Tracon Pharmaceuticals reports collaboration revenue $626,000
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals reports first quarter financial results and provides corporate update.Qtrly loss per share $0.44 collaboration revenue $626,000 versus $1.21 million.  Full Article

Tracon Pharmaceuticals files for sale of up to 3.23 mln shares of co's common stock by Aspire Capital Fund LLC - SEC filing
Monday, 27 Mar 2017 04:50pm EDT 

Tracon Pharmaceuticals Inc : Tracon Pharmaceuticals Inc - files for sale of up to 3.23 million shares of co's common stock by Aspire Capital Fund LLC - SEC filing .Tracon Pharmaceuticals Inc - co will not receive proceeds from sale of shares by the selling stockholder.  Full Article

Tracon Pharmaceuticals announces $21 mln common stock purchase agreement with Aspire Capital Fund
Tuesday, 14 Mar 2017 04:05pm EDT 

Tracon Pharmaceuticals Inc : Tracon Pharmaceuticals announces $21 million common stock purchase agreement with Aspire Capital Fund, LLC . Tracon Pharmaceuticals Inc - aspire capital has made an initial purchase of $1.0 million of Tracon common stock at $4.50 per share . Tracon Pharmaceuticals - aspire capital has committed to purchase up to $20.0 million of additional shares of company's common stock at Tracon's request .Tracon Pharmaceuticals Inc - proceeds from agreement will be used to further advance company's drug development pipeline.  Full Article

Tracon reports fourth quarter results
Tuesday, 28 Feb 2017 04:05pm EST 

Tracon Pharmaceuticals Inc : Tracon Pharmaceuticals reports fourth quarter and year-end 2016 financial results and provides corporate update . Qtrly loss per share $0.45 .Q4 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara

* Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget